BMO Capital Markets Inaugural BMO Obesity Summit
2023 SITC Annual Meeting
San Diego, CA
38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
San Diego, CA
11th annual Obesity Journal Symposium
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Boston, MA
2023 American Association for Cancer Research (AACR) Annual Meeting
Orlando, Fl
SITC 2022 Annual Meeting
European Association for the Study of Diabetes 2022 Annual Conference
EULAR 2021 Virtual Congress - Scleroderma, myositis and related syndromes
EULAR 2021 Virtual Congress - Progress in myositis and scleroderma research - I
Presentation: Phase 3 Trial of Lenabasum, a CB2 Agonist, for the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc)
American College of Rheumatology (“ACR”) Convergence 2020
Virtual
- Abstract #1639: Preliminary Baseline Subject Demographics and Disease Characteristics in a Phase 3 Clinical Trial of the Safety and Efficacy of Lenabasum in Dermatomyositis (DETERMINE)
- Abstract # 1379: Clinical Outcomes Among Participants with Diffuse Systemic Sclerosis Contracting COVID-19 During Clinical Studies of Lenabasum: A Case Series
- Abstract #1949: CB2 Receptor Distribution and Effects of Lenabasum in Dermatomyositis In Vitro
North American Cystic Fibrosis Conference 2020
6th Systemic Sclerosis World E-Congress
- Abstract 120: Provisional American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) Score Correlates with Changes in Patient-reported Outcomes (PROs)
- Poster 158: Health Assessment Questionnaire Disability Index (HAQ-DI) and Patient Global Assessment of Health (PtGA) Correlate with Changes in Patient Reported Outcomes (PROs)
- Poster 159: Patient and Physician Opinion of Clinical Benefit at 3 Months in a Clinical Trial Correlate with Patient Reported Outcomes (PROs)
- Symposium Presentation: The Role of the Endocannabinoid System in Chronic Inflammation and Fibrosis
43rd European Cystic Fibrosis Conference
European League Against Rheumatism (EULAR) 2020 E-Congress
2019 ACR Annual Meeting
Atlanta, Georgia
Oral Presentations:
- Abstract #865: Safety and Efficacy of Lenabasum at 21 Months in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
- Abstract #2843: Safety and Efficacy of Lenabasum at Week 68 in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM) Subjects
Poster:
ICRS 2019 Symposium
Bethesda, MD
EULAR 2019 Annual Meeting
Madrid, Spain
Oral Presentations:
Abstract #OP0241: Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM) Subjects
Abstract #OP0325: Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects (dcSSc)
Poster Presentations:
Abstract #FRI0334: Performance of the Scleroderma Skin Patient-reported Outcome (SSPRO) in a Phase 2 Trial with Lenabasum
Abstract #SAT0303: Design of Phase 3 Study of Lenabasum for the Treatment of Dermatomyositis
Poster Tour:
Abstract #FRI0307: Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Reduces CD4 Cell Populations and Downregulates Type 1 and 2 Interferon Activities in Lesional Dermatomyositis Skin
American College of Rheumatology (“ACR”) 2018 Annual Meeting
Chicago, IL
Presented Posters & Presentations:
- Safety and Efficacy of Lenabasum (JBT-101) in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
- Safety and Efficacy of Lenabasum in Refractory Skin-Predominant Dermatomyositis Subjects Treated in an Open-Label Extension of Trial JBT101-DM-001
- Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Reduces T-Cell Population and Downregulates Type 1 and 2 Interferon Activities in Lesional Dermatomyositis Skin
2018 Annual European Congress of Rheumatology
Amsterdam
Presented Posters & Presentations:
- Safety And Efficacy Of Lenabasum (JBT-101) In Diffuse Cutaneous Systemic Sclerosis Subjects Treated For One Year In An Open-Label Extension Of Trial JBT101-SSc-001
- Safety and Efficacy of Lenabasum in Refractory Skin-Predominant Dermatomyositis Subjects Treated in an Open Label Extension of Trial JBT101-DM-001
- A Phase 2 Study of Safety and Efficacy of Lenabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Refractory Skin-Predominant Dermatomyositis
American College of Rheumatology 2017 Annual Meeting
San Diego, CA
Presented Posters & Presentations:
- Effect of Anabasum (JBT-101) on Gene Expression in Skin Biopsies from Subjects with Diffuse Cutaneous Systemic Sclerosis (dcSSc) and the Relationship of Baseline Molecular Subsets to Clinical Benefit in the Phase 2 Trial
- Prospective Validation of the Scleroderma Skin Patient-reported Outcome (SSPRO) in a Phase 2 Trial of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
- Safety and Efficacy of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc) Subjects Treated in An Open-Label Extension of Trial JBT101-SSc-001
- Comparison of Patients with Dermatomyositis in a Specialty Clinic Versus Clinical Trial with Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist
- Anabasum (JBT-101) Enhances Resolution of Inflammation in Humans
2017 North American Cystic Fibrosis Conference
Indianapolis, IN
Presented Posters:
- A Double-Blind, Placebo Controlled Phase 2 Study in Adults with Cystic Fibrosis of Anabasum, A Selective Cannabinoid Receptor Type 2 Agonist
- Anabasum Reduces Excessive Inflammatory Responses in Cystic Fibrosis Patient-Derived Lung Macrophages
- Anabasum Enhances Resolution of Bacterial-Induced Inflammation in Healthy Humans
2015 ACR Annual Meeting
San Francisco, CA
29th Annual North American Cystic Fibrosis Conference
Phoenix, AZ
Presented Posters:
38th European Cystic Fibrosis Society Conference
Brussels, Belgium
Cystic Fibrosis Workshop
The Langham Hotel, Boston, MA